<DOC>
	<DOCNO>NCT01243489</DOCNO>
	<brief_summary>This study patient 's compliance clinical workaday life aim assess improve CML treatment Germany mean adherence support measure increase adherence awareness physician patient .</brief_summary>
	<brief_title>Compliance : Role Emerges Success Chronic Myelogenous Leukaemia ( CML ) : Evaluation aND Optimisation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Adult ( &gt; 18 year ) CML patient chronic phase Medical history cytogenetically confirm CMLCP presence Philadelphia chromosome bone marrow aspirate ( minimum 20metaphases require ; FISH use ) ; Philadelphia chromosome negative BCR ABLpositive CML patient include ECOG performance status &lt; 2 Imatinib treatment least 1 year show CCyR MMR Prior treatment chemotherapeutics hydroxyurea interferon alpha allow Prior period accelerate phase allow Negative pregnancy test female patient childbearing potential within 7 day initiation study drug Ability understand willingness sign write informed consent document prior study related screening procedure Written inform consent , include consent call interview external , neutral institution . Patients prior blast crisis stem cell transplantation Patients severe medical condition ( ) discretion investigator prohibit participation study ( e.g. , clinically significant heart disease , uncontrolled diabetes , active uncontrolled infection , impaired gastrointestinal function/diseases ) Treatment drug substance , especially know modify cytochrome P450 activity , either discontinue exchange different medication ( see link complete list medication : http : //medicine.iupui.edu/flockhart/table.htm . ) Pregnant breastfeed woman Male female childbearing potential unwilling use contraceptive precaution throughout trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>CML</keyword>
	<keyword>compliance</keyword>
	<keyword>compliance support measure</keyword>
	<keyword>complete cytogenetic response</keyword>
	<keyword>mayor molecular remission</keyword>
	<keyword>Philadelphia chromosome</keyword>
	<keyword>BCR-ABL</keyword>
	<keyword>Imatinib</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>smart blister</keyword>
</DOC>